Albany, NY — 01/15/2018 — Implantable ports (also called portacaths, chest ports, or subcutaneous ports) are thin, hollow, soft tubes made of plastic with a silicon rubber disk at the end. An implantable port is usually inserted into the vein of the patient's chest or the arm. It is one among the group of devices called central venous catheters, wherein the port is attached to the catheter positioned just under the skin of the patient's chest or the arm. The port is most commonly used for administration of chemotherapy as well as oncology drugs. It can be used for IV administration of pain medication antibiotics, nutritional supplements, and blood factors as well as for drawing blood samples.
Estimates by the International Agency for Research on Cancer (IARC) of the WHO indicate the prevalence of 21.7 million new cancer patients across the world in 2017, which would increase the use of chemotherapy in the near future. This, in turn, would augment the demand for implantable ports in the next few years. Major advantages of implantable ports over IV include the fact that, with the use of ports, repeated puncture of the skin is avoided. Also, an implantable port is more efficiently accessed than an IV site. Additionally, certain medications may sometimes lead to tissue damage when administered through IV, which can be avoided by using implantable ports. Once inserted, they can be used for weeks or months depending on the therapy. However, implantable ports may have some disadvantages such as risk of infection at the site of insertion, formation of clots, blockages, and damage caused to the port.
Request Sample Copy of the Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=37772
One of the primary drivers for the implantable ports market is technological advancements. Increasing efforts by manufacturers for the development of highly advanced, technology-based, implantable ports with advanced delivery systems is another driving factor. Manufacturers are also focused on reducing the safety issues associated with implantable ports. PASV valve technology-based Xcela port introduced by AngioDynamics is the first proximally valved CT-rated port. It provides clinicians with saline-only maintenance. Future development of medication and innovative drugs would also fuel for the future expansion in therapy possibilities where usage of port is favored. Some of the restraints for the implantable ports market is availability of peripheral intravenous catheters (PIVCs) and peripherally inserted central catheters (PICCs) and comparatively high price of implantable ports could hamper the market.
Based on product, the implantable ports market can be segmented into venous, arterial, intraperitoneal, and epidural. Based on the number of access points, the implantable ports market has been divided into single-lumen ports and double-lumen ports. Based on material used to manufacture the port, the market has been divided into metal ports (usually made of titanium or stainless steel) and plastic ports (usually made of silicone, polyurethane, polysulfone, polyoxymethylene, or polydamide). Based on end-user, the implantable ports market has been classified into ambulatory surgical centers (ASCs), hospitals, and clinics.
Based on geography, the global implantable ports market has been segregated into North America; Europe, Middle East & Africa (EMEA); and Asia Pacific (APAC). Growth of the implantable ports market in different geographies is dependent on factors such as reimbursement issues, medical practices, and education and training. Considering the revenues generated by implantable ports, North America is expected to be the most attractive market owing to the increasing demand in the U.S due to rise in prevalence of chronic disorders and increase in geriatric population. The implantable ports market in Europe is projected to be driven by factors such as health care industry restructuring, changes in reimbursement policies, and increasing availability of home care facilities in the region. Home care facilities offer an alternative for inpatients, as the patient would return to the hospital only to get implantable ports refilled. The market in developing countries of Asia Pacific such as Japan, China, and India is anticipated to expand at a rapid pace during the forecast period, due to increase in use of chemotherapy and rise in awareness about the use of ports in these countries.
Some of the key players operating in the global implantable ports market are AngioDynamics, Inc., B. Braun Melsungen AG, Cook Medical, C. R. Bard, Inc., Smiths Medical, Vygon S.A., and Teleflex Inc.
Powered by WPeMatico